Chatani M, Matayoshi Y, Masaki N, Inoue T
Department of Radiation Therapy, Osaka University Medical School.
Nihon Igaku Hoshasen Gakkai Zasshi. 1994 Dec 25;54(14):1380-7.
Since September 1980 we have been conducting a prospective randomized trial to determine the best treatment schedule for radiation therapy (XRT) of brain metastasis from lung carcinoma. The first trial (September 1980 to December 1984) used random allocation of two different time-dose radiotherapy schemes: 30 Gy/10 fractions/2 weeks versus 50 Gy/20 fr./4 wks. Treatment results showed no significant difference in neurological improvement or survival between the two arms or in lactate dehydrogenase (LDH) as the most important prognostic factor. The current study (January 1985 to April 1992) examined two sequential trials stratified according to the level of LDH and included 162 patients with brain metastasis from lung carcinoma. Whole brain doses were 30 Gy/10 fr./2 wks (group A, n = 46) or 50 Gy/20 fr./4 wks. (group B, n = 46) in the normal LDH group and 30 Gy/10 fr./2 wks (group C, n = 35) or 20 Gy/5 fr./1 wk. (group D, n = 35) in the high LDH group, while the treatment field was lessened to 30 Gy in group B if possible. The final results showed that 1) the most important prognostic factor as determined by Cox's multivariate analysis was also LDH in the second trial; 2) the incidence of acute side effects tended to depend upon a single dose, i.e., group A (3 Gy) 35% versus group B (2.5 Gy) 21% (p = 0.165), and group C (3 Gy) 23% versus group D (4 Gy) 46% (p = 0.044); 3) median survival time and 1-year survival rates were 5.4 months and 21% in group A, 4.8 months and 17% in group B; 3.4 months and 6% in group C; and 2.4 months and 4% in group D, respectively, and survival curves showed no statistically significant difference between the two treatment groups in each LDH group; 4) improvement in neurological function appeared to increase with total dosage escalation, i.e., 41% in group A versus 45% in group B, and 35% in group C versus 21% in group D (not significant). In conclusion, a short intensive course (30 Gy/10 fr./2 wks) is advantageous for XRT because of the short treatment time and minor acute toxicity in spite of stratification by the level of LDH.
自1980年9月起,我们一直在进行一项前瞻性随机试验,以确定肺癌脑转移放射治疗(XRT)的最佳治疗方案。第一项试验(1980年9月至1984年12月)采用随机分配两种不同的时间-剂量放疗方案:30 Gy/10次/2周与50 Gy/20次/4周。治疗结果显示,两组在神经功能改善、生存率或作为最重要预后因素的乳酸脱氢酶(LDH)方面均无显著差异。当前的研究(1985年1月至1992年4月)检查了两项根据LDH水平分层的连续试验,纳入了162例肺癌脑转移患者。正常LDH组全脑剂量为30 Gy/10次/2周(A组,n = 46)或50 Gy/20次/4周(B组,n = 46),高LDH组为30 Gy/10次/2周(C组,n = 35)或20 Gy/5次/1周(D组,n = 35),而B组如有可能治疗野缩小至30 Gy。最终结果显示:1)Cox多因素分析确定的第二项试验中最重要的预后因素也是LDH;2)急性副作用的发生率似乎取决于单次剂量,即A组(3 Gy)为35%,B组(2.5 Gy)为21%(p = 0.165),C组(3 Gy)为23%,D组(4 Gy)为46%(p = 0.044);3)A组的中位生存时间和1年生存率分别为5.4个月和21%,B组为4.8个月和17%;C组为3.4个月和6%;D组为2.4个月和4%,生存曲线显示各LDH组的两个治疗组之间无统计学显著差异;4)神经功能改善似乎随着总剂量增加而增加,即A组为41%,B组为45%,C组为35%,D组为21%(无显著性差异)。总之,短程强化疗程(30 Gy/10次/2周)对XRT有利,因为治疗时间短且急性毒性小,尽管根据LDH水平进行了分层。